Skip to main content

Advertisement

SpringerLink
Log in

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Current therapeutic modalities for the treatment of systemic sclerosis (SSc) have significant limitations. The window of opportunity to prevent tissue fibrosis and irreversible damage occurs during the early inflammatory phase of this condition. A drug that we believe has promise to exert a desired effect in early SSc is cyclophosphamide (CYC). However, there are only a few published reports regarding the use of cytotoxic immunosuppressive medications at the onset of the illness. The goal of this study was to test the efficacy and toxicity of CYC in patients with early diffuse SSc. The study design was a randomized, unblinded, 18 months per patient trial with a comparison group that received azathioprine (AZ). Thirty patients were assigned to receive oral CYC (2 mg/ kg daily for 12 months and then maintained on 1 mg/kg daily) and 30 patients were assigned to receive oral AZ (2.5 mg/kg daily for 12 months and then maintained on 2 mg/kg daily). During first 6 months of the trial, the patients also received prednisolone, which was started at a dosage of 15 mg daily and tapered to zero by the end of the sixth month. After treatment there was a statistically significant improvement in the modified Rodnan skin score (MRSS), attack frequency of Raynaud’s phenomenon (RP), and erythrocyte sedimentation rate (ESR) in the CYC-group, but not in the AZ-group. The forced vital capacity (FVC) and carbon monoxide diffusing capacity (DLCO) did not change after treatment in the CYC-group, but statistically significantly worsened in the AZ-group. No life-threatening or irreversible adverse reactions were observed in either group. This study showed that CYC is a promising disease modifying medication for SSc as it exhibited a positive influence on the evolution of disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sule SD, Wigley FM (2003) Treatment of scleroderma: an update. Expert Opin Investig Drugs 12:471–482

    Article  PubMed  CAS  Google Scholar 

  2. Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31:196–203

    Article  PubMed  CAS  Google Scholar 

  3. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 12:202–204

    Google Scholar 

  4. Pope JE, Bellamy N, Seibold JR, Baron M, Ellman M, Carette S, et al (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44:1351–1358

    Article  PubMed  CAS  Google Scholar 

  5. Medsger TA Jr, Masi AT (1979) Epidemiology of progressive systemic sclerosis. Clin Rheum Dis 5:15–25

    Google Scholar 

  6. Lally EV, Jimenez SA, Kaplan SR (1988) Progressive systemic sclerosis: mode of presentation, rapidly progressive disease course, and mortality based on an analysis of 91 patients. Semin Arthritis Rheum 18:1–13

    Article  PubMed  CAS  Google Scholar 

  7. Furst DE, Clements PJ, Hills S, Lachenbruch PA, Miller BL, Sterz MG (1989) Immunosuppression with chlorambucil, versus placebo, for scleroderma: results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum 32:584–593

    Article  PubMed  CAS  Google Scholar 

  8. Jones N, Nadashkevich O, Davis P (1997) A comparison of cyclophosphamide versus azathioprine in the treatment of diffuse systemic sclerosis: results of a pilot open study (abstr). J Rheumatol 24:1426

    Google Scholar 

  9. Medsger TA Jr, Steen VD (1996) Classification, prognosis. In: Clements PJ, Furst DE (eds) Systemic sclerosis. Williams & Wilkins, Baltimore, pp 51–64

    Google Scholar 

  10. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Bauman MH, Strange C (1993) Cyclophosphamide and low-dose prednisolone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol 20:838–844

    PubMed  CAS  Google Scholar 

  11. Akesson A, Scheja A, Lundin A, Woolheim FA (1994) Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum 37:729–735

    Article  PubMed  CAS  Google Scholar 

  12. Steen VD, Lanz JR Jr, Conte C, Owens GR, Medsger TA Jr (1994) Therapy for severe interstitial lung disease in systemic sclerosis: a retrospective study. Arthritis Rheum 37:1290–1296

    Article  PubMed  CAS  Google Scholar 

  13. Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PO (1999) Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol 18:455–461

    Article  PubMed  CAS  Google Scholar 

  14. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA (2000) Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med 132:947–954

    PubMed  CAS  Google Scholar 

  15. Griffiths B, Miles S, Moss H, Robertson R, Veale D, Emery P (2002) Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 29:2371–2378

    PubMed  CAS  Google Scholar 

  16. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk M (2003) The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. Clin Rheumatol 22:289–294

    Article  PubMed  CAS  Google Scholar 

  17. Masi AT, Rodnan GP, Medsger TA Jr, Altman RD, D’Angelo WA, Fries JF (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590

    Article  Google Scholar 

  18. Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE (2003) Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 30:1630–1647

    PubMed  Google Scholar 

  19. Ramsden MF, Goldsmith CH, Lee P, Sebaldt R, Baer P (1986) Clinical assessment of scleroderma: observer variation in five methods (abstr). Arthritis Rheum 29:S61

    Google Scholar 

  20. Clements P, Lachenbruch P, Seibold J, White B, Weiner S, Martin R (1995) Inter and intraobserver variability of total skin thickness score (Modified Rodnan TSS) in systemic sclerosis 22:1281–1285

    CAS  Google Scholar 

  21. Mayes MD, O’Donnell, Rothfield NF, Csuka ME (2004) Minocycline is not effective in systemic sclerosis. Arthritis Rheum 50:553–557

    Article  PubMed  CAS  Google Scholar 

  22. Wigley F (1998) Systemic sclerosis clinical features. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby, Philadelphia, pp 7.9.1–7.9.13

    Google Scholar 

  23. Nadashkevich O, Davis P, Fritzler M (2004) A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit (in press)

  24. Lee AT, Burnet S (2002) Corticosteroid-induced scleroderma renal crisis. Med J Aust 177:459

    PubMed  Google Scholar 

  25. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46:2983–2989

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine/Rheumatology, L’viv Medical University, L’viv, Ukraine

    O. Nadashkevich

  2. Division of Rheumatology/Immunology, University of Alberta, Edmonton, Canada

    P. Davis

  3. Division of Rheumatology/Advanced Diagnostic Laboratory, University of Calgary, Calgary, Canada

    M. Fritzler

  4. Institute for Cardiology/Rheumatology, Kiev, Ukraine

    W. Kovalenko

Authors
  1. O. Nadashkevich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Fritzler
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. Kovalenko
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P. Davis.

Additional information

Published online: 14 October 2005

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nadashkevich, O., Davis, P., Fritzler, M. et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol 25, 205–212 (2006). https://doi.org/10.1007/s10067-005-1157-y

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-005-1157-y

Keywords

Search

Navigation